undamentalytics Newsletter
Sign in

Entrada Therapeutics, Inc. income statement

In fiscal 2025, Entrada Therapeutics, Inc. reported revenue of $25.4m, down 87.9% on the year before, operating income of −$158m (a -621.1% margin) and net income of −$144m, or −$3.47 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue129211255
Research and development100125142141
General and administrative32384140
Operating income−347−158−177
Income tax19111
Net income−766−144−166
Diluted EPS−$0.20$1.68−$3.47−$3.97
Diluted shares (average)33m39m41m42m
EBITDA−051−154−173

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BOLT vs TRDAOCGN vs TRDARANI vs TRDAENSC vs TRDA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Entrada Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Entrada Therapeutics, Inc.